Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS

Payment Will Reimburse up to 50% of Cost for Hospitals Treating Medicare Patients in Inpatient Setting NEW HAVEN, Conn. , Aug. 03, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics , Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat


Leave a Reply

Your email address will not be published.